DUBLIN--(BUSINESS WIRE)--The "Global Chemotherapy-Induced Nausea and Vomiting (CINV) & Postoperative Nausea and Vomiting (PONV) Market: Industry Analysis & Outlook (2018-2022)" report has been added to ResearchAndMarkets.com's offering.
This report provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers, key tends & developments and challenges of the market, covering the U.S., Europe along with the global market. The report profiles the key players of the market including Merck & Co., Inc., Kirin Holding Company Limited (ProStrakan), Eisai Co., Ltd. and Helsinn Holding S.A.
The global CINV & PONV market is expected to grow with increasing cancer incidence, growing female population, increasing pharmaceutical R&D spending, growing healthcare expenditure and accelerating economic growth.
Key trends and developments of this market includes progressing drugs under pipeline, high demand for combination therapy and increasing preference for pressure point therapy.
However, there are some factors which can hinder growth of the market including entry of generics, stringent regulations and treatment cost.
The U.S. emerged as a major region for the CINV & PONV market due to rising healthcare concerns and expenditure of the U.S. populace and growing CINV & PONV patient population.
Key Topics Covered
1. CINV & PONV Overview
2. Global CINV & PONV Market
2.1 Global CINV Market Forecast by Value
2.2 Global PONV Market Forecast by Value
3. Regional CINV & PONV Market
3.1 The U.S. CINV & PONV Market Forecast by Value
3.2 The U.S. CINV & PONV Drugs Revenue by Categories
3.3 The U.S. CINV & PONV Drugs Revenue
3.4 The U.S. CINV Drugs Revenue
3.5 The U.S. PONV Patient Population Forecast
3.6 The U.S. PONV Drugs Revenue
3.7 Europe CINV Drugs Revenue
4. Market Dynamics
4.1 Growth Drivers
4.2 Key Trends and Developments
5. Competitive Landscape
5.1 Global Market
5.2 The U.S.
6. Company Profiles
6.1 Merck & Co. Inc.
6.2 Eisai Co. Ltd.
6.3 Kirin Holding Company Limited (ProStrakan)
6.4 Helsinn Holding S.A.
For more information about this report visit https://www.researchandmarkets.com/research/fzdwtp/global?w=4